Neurogene Inc. Files 8-K: Regulation FD Disclosure
Ticker: NGNE · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1404644
Sentiment: neutral
Topics: 8-K, regulatory-disclosure, company-information
TL;DR
Neurogene filed an 8-K for a Reg FD disclosure on Nov 20.
AI Summary
Neurogene Inc. filed an 8-K on November 21, 2024, reporting an event on November 20, 2024. The filing is a Regulation FD Disclosure. The company, formerly known as Neoleukin Therapeutics, Inc., is based in New York, NY.
Why It Matters
This filing indicates a disclosure event under Regulation FD, which ensures that material information is disseminated to all investors simultaneously.
Risk Assessment
Risk Level: low — This is a standard regulatory filing without immediate financial or operational implications disclosed.
Key Numbers
- 001-36327 — SEC File Number (Identifies the company's filing with the SEC)
- 98-0542593 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Neoleukin Therapeutics, Inc. (company) — Former company name
- November 20, 2024 (date) — Earliest event date
- November 21, 2024 (date) — Filing date
- New York, NY (location) — Principal executive offices
FAQ
What specific event triggered the Regulation FD Disclosure for Neurogene Inc. on November 20, 2024?
The provided text does not specify the exact event that triggered the Regulation FD Disclosure; it only states that the filing is a Regulation FD Disclosure and the earliest event date was November 20, 2024.
What was Neurogene Inc.'s former name?
Neurogene Inc.'s former name was Neoleukin Therapeutics, Inc.
When was the 8-K filing submitted to the SEC?
The 8-K filing was submitted to the SEC on November 21, 2024.
Where are Neurogene Inc.'s principal executive offices located?
Neurogene Inc.'s principal executive offices are located at 535 W 24th Street, 5th Floor, New York, NY 10011.
What is the SIC code for Neurogene Inc.?
The Standard Industrial Classification (SIC) code for Neurogene Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-11-21 16:01:15
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Market
Filing Documents
- ngne-20241120.htm (8-K) — 23KB
- 0001404644-24-000109.txt ( ) — 146KB
- ngne-20241120.xsd (EX-101.SCH) — 2KB
- ngne-20241120_lab.xml (EX-101.LAB) — 22KB
- ngne-20241120_pre.xml (EX-101.PRE) — 13KB
- ngne-20241120_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. The participant in Neurogene's ongoing Phase 1/2 clinical trial for Rett syndrome who was dosed on November 5 with 3E15 vg of NGN-401 and was previously reported to be in critical condition, has died following complications from a rare and life-threatening hyperinflammatory syndrome associated with systemic exposure to high doses of adeno-associated virus (AAV). The FDA allowed Neurogene to proceed with the Phase 1/2 trial using the 1E15 vg dose for both the pediatric and adolescent/adult cohorts. Neurogene will also incorporate the 1E15 vg dose in its future registrational trial design planning. The information in this Item 7.01 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: November 21, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer